Skip to main content
SpringerLink
Log in

Economic Cost of Male Erectile Dysfunction Using a Decision Analytic Model

For a Hypothetical Managed-Care Plan of 100 000 Members

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Objective: This paper examined the economic cost of male erectile dysfunction (ED) for a hypothetical managed-care (MC) model.

Design and Setting: A prevalence-based cost-of-illness approach was used to estimate the direct medical cost for ED treatment. A treatment plan algorithm was developed from a MC perspective to model the initial treatment selection of various patient groups [vacuum erection device, intracavernosal injection (ICI) therapy, transurethral alprostadil suppository, sildenafil, testosterone replacement therapy, penile prosthesis] and their therapy outcomes during a 3-year period. Overall cost was based on 1998 US dollars. Total direct medical cost of ED considered in this model included the cost of initial physician consultation and evaluation, the cost incurred by patients from various treatment groups (pharmacological and surgical options), as well as the cost related to patients’ follow-up for treatment within the 3-year period. Consideration for therapy switches made by patients who failed initial therapy was included as part of the clinical assumptions for this model. Treatment response and expected outcomes (dropouts) were considered for the various treatment options.

Participants: A total of 100 000 enrolled members were included in the study.

Main outcome measures and results: The total cost of ED was $US3 204 792 for the 3-year period in the hypothetical MC plan. The treatment portion accounted for approximately 80% of the total cost while the cost of medical services and diagnostic tests were minimal in comparison. The 3 year total cost of nonsurgical treatment was $US2 473 045. Costs associated with each treatment alternative were $US81 866 (testosterone transdermal patch), $US51 930 (vacuum erection device), $US384 624 (ICI therapy), $US226 483 (transurethral alprostadil suppository) and $US1 728 142 (sildenafil citrate). Results from the model showed a noticeable trend of decreasing cost patterns over time and reflected the attrition observed for many of the standard medical therapies for ED.

Conclusions: Sildenafil and the vacuum erection device should be considered as first-line management strategies for ED whereas ICI therapy, transurethral alprostadil suppository and penile prosthesis implant should be reserved for second- or third-line therapy. Because costs associated with switches related to successive treatment failures can be high, treatment considerations should, therefore, focus on achieving long term patient satisfaction. The patient’s preferred treatment choice, using goal-directed therapy during the initial consultation and evaluation visit, should be used.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Table III
Table IV
Table V
Table VI
Table VII
Table VIII
Table IX

Similar content being viewed by others

References

  1. National Institute of Health. Impotence. Natl Inst Health Consens Dev Conf Consens Statement 1992; 10 (4): 1–33

    Google Scholar 

  2. Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am 1995; 22 (4): 699–709

    PubMed  CAS  Google Scholar 

  3. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States. JAMA 1999; 281: 537–44

    Article  PubMed  CAS  Google Scholar 

  4. National Center for Health Statistics. In: Nelson C, McLemore T, editors. The National Ambulatory Medical Care Survey: United States 1975–81 and 1985 trends. Vital and Health Statistics: series 13, no.93. Washington, DC.: Government Printing Office, 1988. DHHS publication no.: (PHS) 88–1754

  5. National Center for Health Statistics. National Hospital Discharge Survey, 1985. Bethesda (MD): Department of Health and Human Services, 1989. DHHS Publication no.: 87–1751

    Google Scholar 

  6. Donatucci CF, Lue TF. Erectile dysfunction in men under 40: etiology and treatment choice. Int J Impot Res 1993; 5: 97–103

    PubMed  CAS  Google Scholar 

  7. Krane RJ, Goldstein I, Saenz De Tejada I. Impotence. N Engl J Med 1989; 321 (24): 1648–59

    Article  PubMed  CAS  Google Scholar 

  8. Zonszein J. Diagnosis and management of endocrine disorders of erectile dysfunction. Urol Clin North Am 1995; 22 (4): 789–802

    PubMed  CAS  Google Scholar 

  9. Wein AJ, Van Arsdalen KN. Drug-induced male sexual dysfunction. Urol Clin North Am 1988; 15 (1): 23–31

    PubMed  CAS  Google Scholar 

  10. Smith AD. Psychologic factors in the multidisciplinary evaluation and treatment of erectile dysfunction. Urol Clin North Am 1988; 15 (1): 41–51

    PubMed  CAS  Google Scholar 

  11. Kuritzky L. Management of impotence in primary care. Compr Ther 1998; 24 (3): 137–46

    PubMed  CAS  Google Scholar 

  12. Mobley DF, Baum N. When patients request the impotence pill. Tips for office evaluation and treatment. Postgrad Med 1998; 104 (2): 55–66

    Article  PubMed  CAS  Google Scholar 

  13. Tiefer L, Schuetz-Mueller D. Psychological issues in diagnosis and treatment of erectile disorders. Urol Clin North Am 1995; 22 (4): 767–73

    PubMed  CAS  Google Scholar 

  14. Jackson SE, Lue TF. Erectile dysfunction: therapy health outcomes. Urology 1998; 51 (6): 874–82

    Article  PubMed  CAS  Google Scholar 

  15. Montague DK, Barada JH, Belker AM, et al. Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. J Urol 1996; 156: 2007–11

    Article  PubMed  CAS  Google Scholar 

  16. Turner LA, Althof SE, Levine SB, et al. Treating erectile dysfunction with external vacuum devices: impact upon sexual, psychological and marital functioning. J Urol 1990; 144: 79–82

    PubMed  CAS  Google Scholar 

  17. Vrijhof HJEJ, Delaere KPJ. Vacuum constriction devices in erectile dysfunction: acceptance and effectiveness in patients with impotence of organic ormixed aetiology. Br J Urol 1994; 74: 102–5

    Article  PubMed  CAS  Google Scholar 

  18. Willke RJ, Glick HA, McCarron TJ, et al. Quality of life effects of alprostadil therapy for erectile dysfunction. J Urol 1997; 157: 2124–8

    Article  PubMed  CAS  Google Scholar 

  19. Armstrong DKB, Convery AG, Dinsmore WW. Reasons for patient drop-out from an intracavernous auto-injection programme for erectile dysfunction. Br J Urol 1994; 74: 99–101

    Article  PubMed  CAS  Google Scholar 

  20. Whale RK, Merrill DC. Patient satisfaction with Mentor inflatable penile prosthesis. Urology 1991; 37 (6): 531–9

    Article  Google Scholar 

  21. Pedersen B, Tiefer L, Ruiz M, et al. Evaluation of patients and partners 1 to 4 years after penile prosthesis surgery. J Urol 1988; 139: 956–8

    PubMed  CAS  Google Scholar 

  22. Lewis RW. Long term results of penile prosthetic implants. Urol Clin North Am 1995; 22 (4): 847–56

    PubMed  CAS  Google Scholar 

  23. Fishman IJ. Complicated implantation of inflatable penile prosthesis. Urol Clin North Am 1987; 14 (1): 217–39

    PubMed  CAS  Google Scholar 

  24. Kabalin JN, Kessler R. Infectious complications of penile prosthesis surgery. J Urol 1988; 139: 953–5

    PubMed  CAS  Google Scholar 

  25. Thomalla JV, Thompson ST, Rowland RG, et al. Infectious complications of penile prosthetic implants. J Urol 1987; 138: 65–7

    PubMed  CAS  Google Scholar 

  26. Sharaby JS, Benet AE, Melman A. Penile revascularization. Urol Clin North Am 1995; 22 (4): 821–32

    PubMed  CAS  Google Scholar 

  27. Wespes E, Schulman C. Venous impotence: pathophysiology, diagnosis and treatment. J Urol 1993; 149: 1238–45

    PubMed  CAS  Google Scholar 

  28. Bennett AH. Venous arterialization for erectile impotence. Urol Clin North Am 1988; 15 (1): 111–3

    PubMed  CAS  Google Scholar 

  29. Lewis RW. Venous surgery for impotence. Urol Clin North Am 1988; 15 (1): 115–21

    PubMed  CAS  Google Scholar 

  30. Jarow JP, DeFranzo AJ. Long term results of arterial bypass surgery for impotence secondary to segmental vascular disease. J Urol 1996; 156: 982–5

    Article  PubMed  CAS  Google Scholar 

  31. Freedman AL, Neto FC, Mehringer CM, et al. Long-term results of penile vein ligation for impotence from venous leakage. J Urol 1993; 149: 1301–3

    PubMed  CAS  Google Scholar 

  32. IMS America. Viagra challenges drug coverage policy [online]. Available from: URL: http://www.IMS-america.com/communications/HF_ViagraIns.htm [Accessed 1998 Nov 23]

  33. Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics 1992; 2 (1): 1–4

    Article  PubMed  CAS  Google Scholar 

  34. Johannesson M. Economic evaluation of drugs and its potential uses in policy making. Pharmacoeconomics 1995; 8 (3): 190–8

    Article  PubMed  CAS  Google Scholar 

  35. Hodgson TA. Costs-of-illness in cost-effectiveness analysis: a review of the methodology. Pharmacoeconomics 1994; 6 (6): 536–52

    Article  PubMed  CAS  Google Scholar 

  36. Scitovsky, AA. Estimating the direct costs of illness. Milbank Mem Fund Q 1982; 60 (3): 463–91

    Article  CAS  Google Scholar 

  37. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994; 151: 54–61

    PubMed  CAS  Google Scholar 

  38. Kinsey AC, Pomeroy W, Martin CE. Sexual behavior in the human male. Philadelphia (PA): W.B. Saunders, 1948: 218–62

    Google Scholar 

  39. Day JC. Population projections of the United States by age, sex, race, and hispanic origin: 1995 to 2050. U. S. Bureau of the Census: Current Population Reports, P25–1130, U.S. Washington, DC: Government Printing Office, 1996

    Google Scholar 

  40. Managed care. In: Cherner LL, editor. A complete guide for the healthcare professional-facts, figures, analysis. The universal healthcare almanac 1998. Pheonix (AR): R-C Publications; 1999: 98–3

  41. Lue TF. Impotence: a patient’s goal-directed approach to treatment. World J Urol 1990; 8: 67–74

    Article  Google Scholar 

  42. Lue TF. Erectile dysfunction: problems and challenges [editorial]. J Urol 1993; 149: 1256–7

    PubMed  CAS  Google Scholar 

  43. Long Jr RL, Sherman LS, Lombardi TJ. A goal-oriented, cost-effective approach to the diagnosis and treatment of male erectile dysfunction. Kentucky Med Assoc J 1995; 93: 500–8

    Google Scholar 

  44. Burnett AL. Erectile dysfunction: a practical approach for primary care. Geriatrics 1998; 53 (2): 34–48

    PubMed  CAS  Google Scholar 

  45. Knispel HH, Huland H. Influence of cause on choice of therapy in 174 patients with erectile dysfunction. J Urol 1992; 147: 1274–6

    PubMed  CAS  Google Scholar 

  46. Hanash KA. Comparative results of goal oriented therapy for erectile dysfunction. J Urol 1997; 157: 2135–8

    Article  PubMed  CAS  Google Scholar 

  47. Jarow JP, Nana-Sinkam P, Sabbagh M, et al. Outcome analysis of goal-directed therapy for impotence. J Urol 1996; 155: 1609–12

    Article  PubMed  CAS  Google Scholar 

  48. Baum N, Rhodes D. A practical approach to the evaluation and treatment of erectile dysfunction: a private practitioner’s viewpoint. Urol Clin North Am 1995; 22 (4): 865–77

    PubMed  CAS  Google Scholar 

  49. Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997; 158: 1764–7

    Article  PubMed  CAS  Google Scholar 

  50. Levine LA, Lenting EL. Use of nocturnal penile tumescence and rigidity in the evaluation of male erectile dysfunction. Urol Clin North Am 1995; 22 (4): 775–88

    PubMed  CAS  Google Scholar 

  51. Lottman PEM, Hendriks JCM, Vruggink PA, et al. The impact of marital satisfaction and pyschological counseling on the outcome of ICI-treatment in men with ED. Int J Impotence Res 1998; 10: 83–7

    Article  CAS  Google Scholar 

  52. Morales A, Johnston B, Heaton JPW, et al. Testosterone supplementation for hypogondal impotence: assessment of biochemical measures and therapeutic outcomes. J Urol 1997; 157: 849–54

    Article  PubMed  CAS  Google Scholar 

  53. Govier FE, McClure RD, Kramer-Levien D. Endocrine screening for sexual dysfunction using free testosterone determinations. J Urol 1996; 156: 405–8

    Article  PubMed  CAS  Google Scholar 

  54. Jr Jordan WP, Atkinson LE, Lai C. Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. Clin Ther 1998; 20 (1): 80–7

    Article  PubMed  CAS  Google Scholar 

  55. McClellan KJ, Goa KL. Transdermal testosterone. Drugs 1998; 55 (2): 253–8

    Article  PubMed  CAS  Google Scholar 

  56. Arver S, Dobs AS, Meikle AW, et al. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 1996; 15 (5): 1604–8

    Google Scholar 

  57. Arver S, Dobs AS, Meikle AW, et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol 1997; 47 (6): 727–37

    Article  CAS  Google Scholar 

  58. Mentor urology products surgical price list. Santa Barbara (CA): Mentor Corporation, 1998

  59. Fallon B, Intracavernous injection therapy formale erectile dysfunction. Urol Clin North Am 1995; 22 (4): 833–45

    PubMed  CAS  Google Scholar 

  60. Fallon B, Intracavernous injection therapy formale erectile dysfunction. Urol Clin North Am 1995; 22 (4): 833–45

    PubMed  CAS  Google Scholar 

  61. Engel JD, McVary KT. Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy. Urology 1998; 51: 687–92

    Article  PubMed  CAS  Google Scholar 

  62. Padma-Nathan H, Hellstrom WJG, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997; 336: 1–7

    Article  PubMed  CAS  Google Scholar 

  63. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397–404

    Article  PubMed  CAS  Google Scholar 

  64. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996; 155: 802–15

    Article  PubMed  CAS  Google Scholar 

  65. Medical Economics. 1998 Physician’s Desk Reference: product information for testoderm TTS. Oradell (NJ): Medical Economics, 1998

    Google Scholar 

  66. Wilson DE, Kaidbey K, Boike SC, et al. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Clin Ther 1998; 20 (2): 299–306

    Article  PubMed  Google Scholar 

  67. Cookson MS, Nadig PW. Long-term results with the vacuum constriction device. J Urol 1993; 149: 290–4

    PubMed  CAS  Google Scholar 

  68. Lundberg L, Olsson J, Kihl B. Long term experience of self-injection therapy with prostaglandin E1 for erectile dysfunction. Scand J Urol Nephrol 1996; 30: 395–7

    Article  PubMed  CAS  Google Scholar 

  69. Virag R, Shoukry K, Floresco J, et al. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8 years experience with 615 cases. J Urol 1991; 145: 287–93

    PubMed  CAS  Google Scholar 

  70. Sundaram CP, Thomas W, Pryor LE, et al. Long term follow-up of patients receiving injection therapy for erectile dysfunction. Urology 1997; 49: 932–5

    Article  PubMed  CAS  Google Scholar 

  71. Williams G, Abbou CC, Amar ET, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. Br J Urol 1998; 81 (6): 889–94

    Article  PubMed  Google Scholar 

  72. Goldstein I, Newman L, Baum N, et al. Safety and efficacy outcome of Mentor Alpha-1 inflatable penile prosthesis implantation for impotence treatment. J Urol 1997; 157: 833–9

    Article  PubMed  CAS  Google Scholar 

  73. Weinstein MC. Challenges for cost-effectiveness research. Med Decis Making 1986; 6 (4): 194–8

    Article  PubMed  CAS  Google Scholar 

  74. Derry FA, Dinsmore WW, Fraser M, et al. Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury. Neurology 1998; 51 (6): 1629–33

    Article  PubMed  CAS  Google Scholar 

  75. Zippe CD, Kedia AW, Kedia K, et al. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology 1998; 52 (6): 963–6

    Article  PubMed  CAS  Google Scholar 

  76. Price DE, Gingell JC, Gepi-Attee S, et al. Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 1998; 15 (10): 821–5

    Article  PubMed  CAS  Google Scholar 

  77. Rendell MS, Rajfer J, Wicker PA, et al. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial [abstract]. JAMA 1999; 281: 421–6

    Article  PubMed  CAS  Google Scholar 

  78. Competition mounts but ’Viagra’ stays on top. Inpharma 1998; 1149: 11–2

  79. Pfizer. Product package insert for sildenafil citrate (Viagra). New York: Pfizer, 1998

    Google Scholar 

  80. FDA. Postmarketing safety of sildenafil citrate (Viagra). Available from: URL: http://www.fda.gov/cder/consumerinfo/Viagra/safety3.html [Accessed 1999 Feb 22]

  81. IMS America. IMS Health forecasts Viagra sales to reach $1 billion in first year. Available from: URL: http://www.IMSamerica.com/communications/pr_Viagra_July6.html [Accessed 1998 Nov 22]

  82. Levy RA. Prescription cost sharing: economic and health impacts, and implications for health policy. Pharmacoeconomics 1992; 2 (3): 219–37

    Article  PubMed  CAS  Google Scholar 

  83. Burstall ML. Copayments for medicines: how much should patients pay? [editorial]. Pharmacoeconomics 1994; 6 (3): 187–92

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Health Outcomes Research Design Consultants LLC, 9 East Loockerman St, Suite 205, Dover, Delaware, 19901, USA

    Howard L. Tan

Authors
  1. Howard L. Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Howard L. Tan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tan, H.L. Economic Cost of Male Erectile Dysfunction Using a Decision Analytic Model. Pharmacoeconomics 17, 77–107 (2000). https://doi.org/10.2165/00019053-200017010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200017010-00006

Keywords

Search

Navigation